Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Fish Polyclonal EPAS1 Primary Antibody for ChIP, ELISA - ABIN151051
Conrad, Freeman, Beitner-Johnson, Millhorn: EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. in The Journal of biological chemistry 1999
Show all 500 Pubmed References
Hamster Monoclonal EPAS1 Primary Antibody for ChIP, ELISA - ABIN151063
Bernhardt, Wiesener, Weidemann, Schmitt, Weichert, Lechler, Campean, Ong, Willam, Gretz, Eckardt: Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. in The American journal of pathology 2007
Show all 149 Pubmed References
Hamster Monoclonal EPAS1 Primary Antibody for ELISA, IHC - ABIN250056
Harvey, Kind, Pantaleon, Armstrong, Thompson: Oxygen-regulated gene expression in bovine blastocysts. in Biology of reproduction 2004
Show all 19 Pubmed References
Hamster Monoclonal EPAS1 Primary Antibody for ELISA, ICC - ABIN250055
Mekhail, Gunaratnam, Bonicalzi, Lee: HIF activation by pH-dependent nucleolar sequestration of VHL. in Nature cell biology 2004
Show all 15 Pubmed References
Fish Polyclonal EPAS1 Primary Antibody for ELISA, ICC - ABIN249868
Alvarez-Tejado, Naranjo-Suarez, Jiménez, Carrera, Landázuri, del Peso: Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. in The Journal of biological chemistry 2001
Show all 17 Pubmed References
Human Monoclonal EPAS1 Primary Antibody for IHC (fro), IHC (p) - ABIN1742588
Wiesener, Turley, Allen, Willam, Eckardt, Talks, Wood, Gatter, Harris, Pugh, Ratcliffe, Maxwell: Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. in Blood 1998
Show all 4 Pubmed References
Human Polyclonal EPAS1 Primary Antibody for IF (p), IHC (p) - ABIN686662
Li, Chen, Shao, Tang, Chen, Chen, Xu: Oxidative stress induces the decline of brain EPO expression in aging rats. in Experimental gerontology 2016
Human Monoclonal EPAS1 Primary Antibody for AA, ELISA - ABIN863099
Kim, Perera, Zhou, Carretero, Yeh, Heathcote, Jackson, Nikolinakos, Ospina, Naumov, Brandstetter, Weigman, Zaghlul, Hayes, Padera, Heymach, Kung, Sharpless, Kaelin, Wong: HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. in The Journal of clinical investigation 2009
Show all 4 Pubmed References
Human Monoclonal EPAS1 Primary Antibody for IHC (p) - ABIN2473999
Pike, Phadwal, Simon, Harris: ATF4 orchestrates a program of BH3-only protein expression in severe hypoxia. in Molecular biology reports 2012
Hamster Monoclonal EPAS1 Primary Antibody for ELISA, FACS - ABIN406865
Su, Li, Cui, Ji, Geng, Chai, Ma, Bai, Yang, Wuren, Ge, Rondina: The Local HIF-2α/EPO Pathway in the Bone Marrow is Associated with Excessive Erythrocytosis and the Increase in Bone Marrow Microvessel Density in Chronic Mountain Sickness. in High altitude medicine & biology 2015
HIF-2a regulates non-canonical glutamine (show GFPT1 Antibodies) metabolism via activation of PI3K (show PIK3CA Antibodies)/mTORC2 (show CRTC2 Antibodies) pathway and GOT1 (show GOT1 Antibodies) expression in human pancreatic ductal adenocarcinoma.
epigenomic profiling of clear cell renal cell carcinoma (show MOK Antibodies) (ccRCC) establishes a compendium of somatically altered cis (show CISH Antibodies)-regulatory elements, uncovering new potential targets including ZNF395 (show ZNF395 Antibodies). Loss of VHL (show VHL Antibodies), a ccRCC signature event, causes pervasive enhancer malfunction, with binding of enhancer-centric HIF2a and recruitment of histone acetyltransferase p300 (show EP300 Antibodies) at preexisting lineage-specific promoter-enhancer complexes
We studied the hypoxic activation of the transcription factors HIF-1alpha (show HIF1A Antibodies) and HIF-2alpha in endothelial cells within a spatial linear gradient of oxygen. Quantification of the nuclear to cytosolic ratio of HIF immunofluorescent staining demonstrated that the threshold for HIF-1alpha (show HIF1A Antibodies) activation was below 2.5% O2 while HIF-2alpha was activated throughout the entire linear gradient.
miRNA-101 level is decreased in RCC (show XRCC1 Antibodies) tissues/cells, which could be responsible for DNA-PKcs (show PRKDC Antibodies) overexpression and DNA-PKcs (show PRKDC Antibodies) mediated oncogenic actions; DNA-PKcs (show PRKDC Antibodies) over-expression regulates mTORC2 (show CRTC2 Antibodies)-AKT (show AKT1 Antibodies) activation, HIF-2alpha expression and RCC (show XRCC1 Antibodies) cell proliferation
report shows that somatic gain-of-function HIF2A mutations are present in 20% of gangliocytic paragangliomas (GPGLs) in the present series; the mutations appear to be located in the hot spot of the oxygen-sensing domain of HIF-2alpha, resulting in increased HIF-2alpha stabilization and impaired ubiquitination and degradation
these findings establish a new link between HIF-2alpha and MAPK (show MAPK1 Antibodies)-signaling that mediates the adaptive regulation of mitochondrial gene expression under low oxygen tension.
HIF-2alpha and VM were overexpressed in pancreatic cancer tissues and were associated with poor pathological characteristics. HIF-2alpha contributes to VM formation by regulating the expression of VE-cadherin (show CDH5 Antibodies) through the binding of the transcription factor Twist1 (show TWIST1 Antibodies) to the promoter of VE-cadherin (show CDH5 Antibodies) in pancreatic cancer both in vitro and in vivo.
HIF-2alpha facilitated the preservation of Human placenta-derived mesenchymal stem cell stemness and promoted their proliferation by regulating CCND1 (show CCND1 Antibodies) and MYC (show MYC Antibodies) through the MAPK/ERK (show MAPK1 Antibodies) signaling pathway.
Results showed that HIF-1alpha (show HIF1A Antibodies) and HIF-2alpha were highly expressed in vascular malformation (GIVM) and suggest that they induced angiogenesis in GIVM.
The present study demonstrates that hypoxia-induced downregulation of Dicer (show DICER1 Antibodies) serves as key mechanism in the maintenance of the hypoxic response in HCC (show FAM126A Antibodies) and that prevention of hypoxic suppression of Dicer (show DICER1 Antibodies) not only alleviates hypoxia-induced upregulation of HIF1alpha (show HIF1A Antibodies) and HIF2alpha and other key hypoxia-responsive/HIF target genes, but also inhibits hypoxia-induced metastatic phenotypes such as EMT (show ITK Antibodies) and increased cell motility.
Defect in nephron formation in PHD2 (show EGLN1 Antibodies)/PHD3 (show EGLN3 Antibodies) double mutants required intact hypoxia-inducible factor-2 signaling and was dependent on the extent of stromal hypoxia-inducible factor activation. Thus, hypoxia-inducible factor prolyl-4-hydroxylation in renal interstitial cells is critical for normal nephron formation.
Absence of Hif2a in retinal neuroprogenitor cells causes a marked reduction of proliferating endothelial cells at the angiogenic front. This results in delayed retinal vascular development, fewer major retinal vessels and reduced density of the peripheral deep retinal vascular plexus.
HIF2alpha is linked to tumor suppression in neuroblastoma (show ARHGEF16 Antibodies).
The pseudo-hypoxic phenotype of stem-like glioma cells is achieved by stabilization of HIF-2a through interaction with CD44 (show CD44 Antibodies), independently of oxygen.
HIF-1alpha (show HIF1A Antibodies)-dependent, HIF-2alpha-independent angiogenesis and constitutive diuresis is caused by Vhl (show VHL Antibodies) deletion in renal epithelia
A novel biological pathway has been discovered of soluble biglycan (show BGN Antibodies) inducing HIF-2alpha protein stabilization and Epo (show EPO Antibodies) production presumably in an oxygen-independent manner, ultimately giving rise to secondary polycythemia.
Data suggest that chronic hypoxia enhances HIF-2alpha stability, which causes increased arginase expression and dysregulates normal vascular NO homeostasis.
Data show that Tet1 (show TET1 Antibodies) modulates HIF-2alpha and HIF-1alpha (show HIF1A Antibodies) through different mechanisms.
intestine HIF-2alpha regulates ceramide metabolism mainly from the salvage pathway, by positively regulating the expression of Neu3 (show Neu3 Antibodies), the gene encoding neuraminidase 3 (show Neu3 Antibodies). These results suggest that intestinal HIF-2alpha could be a viable target for hepatic steatosis therapy
endothelial EPAS1 has a global protective role during glomerular hypertensive injuries without influencing the hypertensive effect of angiotensin II
immunostaining for HIF-1alpha (show HIF1A Antibodies) and HIF-2alpha was observed during endochondral ossification; only HIF-2alpha was present at sites of intramembranous ossification
There was an association of an EPAS1 (HIF2alpha) double variant in the oxygen degradation domain of EPAS1 in Angus cattle with high altitude pulmonary hypertension (HAPH). There was upregulation of 26 of 27 HIF2alpha target genes in EPAS1 carriers with HAPH.
This gene encodes a transcription factor involved in the induction of genes regulated by oxygen, which is induced as oxygen levels fall. The encoded protein contains a basic-helix-loop-helix domain protein dimerization domain as well as a domain found in proteins in signal transduction pathways which respond to oxygen levels. Mutations in this gene are associated with erythrocytosis familial type 4.
endothelial PAS domain protein 1
, endothelial PAS domain-containing protein 1-like
, HIF-1-alpha-like factor
, HIF-1alpha-like factor
, PAS domain-containing protein 2
, basic-helix-loop-helix-PAS protein MOP2
, class E basic helix-loop-helix protein 73
, endothelial PAS domain-containing protein 1
, hypoxia-inducible factor 2 alpha
, hypoxia-inducible factor 2-alpha
, member of PAS protein 2
, HIF-related factor
, HIF1 alpha-like factor
, HIF1alpha-like factor
, HLF (HIF1alpha-like factor)
, Hif like protein
, hypoxia inducible transcription factor 2alpha
, HIF-2 alpha
, HIF2 alpha
, hypoxia inducible factor 2, alpha subunit
, hypoxia inducible factor 2a